Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

What Was Tested

The paper reports a study of Orforglipron (Foundayo, non-peptide), published as a randomized controlled trial.

The researchers aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Orforglipron (Foundayo, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Orforglipron (Foundayo, non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Orforglipron (Foundayo, non-peptide) group a baseline to be compared against.

This 72-week, phase 3, double-blind, placebo-controlled trial was conducted across 136 sites in ten countries.

The primary endpoint was the mean percent change in bodyweight from baseline to week 72.

This trial was registered at ClinicalTrials.gov (NCT05872620) and is completed.

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin, Hypoglycemic Agents, Obesity and Fluorine Compounds.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Orforglipron (Foundayo, non-peptide).

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Lancet (London, England)), a journal based in England.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.